恒瑞医药HRS-2141片临床试验获批

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS-2141 tablets for type 2 diabetes, marking a significant step in the development of a novel treatment option in the market [1] Group 1 - The approved clinical trial is for HRS-2141 tablets (I) and (II), which are fixed-dose combination formulations [1] - The pharmacological mechanism of HRS-2141 is designed to complement and synergistically lower blood sugar levels [1] - Currently, there are no similar drugs approved for marketing in both domestic and international markets [1]